New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
13:29 EDTTEVA, GALEGalena Biopharma to partner with Teva in Israel
Galena Biopharma (GALE), a biotechnology company focused on oncology treatments, announced earlier today that it has signed an agreement with a subsidiary of Teva Pharmaceutical Industries for the commercialization of NeuVax, a breast cancer treatment, in Israel. Under the agreement, Teva Israel will assume responsibility for regulatory registration in Israel, provide financial support for local development, and will commercialize the product in the region. Specific financial terms were not disclosed, but the agreement allows for significant royalty payments to Galena Biopharma on future sales.
News For TEVA;GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 18, 2015
07:13 EDTTEVATeva volatility elevated, shares near four year high
Subscribe for More Information
March 17, 2015
19:42 EDTTEVAOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTTEVAIgnyta acquires 4 oncology R&D assets from Teva for 1.5M shares of common stock
Teva (TEVA) and Ignyta (RXDX) announced the acquisition by Ignyta of the worldwide rights and assets relating to four targeted oncology development programs in exchange for 1.5M shares of Ignyta’s common stock. Concurrently, Ignyta has entered into stock purchase agreements with Teva, and selected additional healthcare investors, whereby Teva will purchase a further 1.5 million shares of common Ignyta stock at a price of $10 per share in a registered direct offering. The other investors will purchase an additional 2.7M shares at $10 per share, valuing the total offering at approximately $41.6M. Under the terms of the asset purchase agreement with Teva, Ignyta is acquiring all of Teva’s assets and worldwide rights relating to four oncology development programs in exchange for 1.5M shares of Ignyta’s common stock. Teva has agreed not to sell or otherwise transfer any of these shares until March 17, 2016, and Ignyta is required to register the resale of these shares with the SEC prior to such date. Ignyta also assumed all of Teva’s ongoing obligations under certain contracts relating to the purchased programs, including the agreements under which Teva in-licensed rights to the assets.
10:26 EDTTEVAOptions with increasing implied volatility
Subscribe for More Information
March 16, 2015
11:40 EDTTEVAEnzo Biochem to request rehearing of court of appeals decision
Enzo Biochem (ENZ) said, acting upon advice of counsel, that it disagrees with the March 16 split 2-to-1 decision of the Court of Appeals sitting in panel for the Federal Circuit that reverses-in-part and vacates-in-part the judgment in Enzo’s favor that Applera Corp., now Life Technologies (LIFE), infringed Enzo’s patents covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code, and remands the case to the District Court as to whether the accused product infringes. Counter to the District Court’s construction of the ‘767 patent as allowing for directly-detectable labels on nucleotides and polynucleotides, and counter to the jury’s verdict that the patent describes such labelling, the Court of Appeals, held such labelling excluded by claim 1 of that patent. Enzo notes also that the Court’s partial vacatur and reversal of the judgment does not end the case, but remands the case back to the District Court to find whether the accused product infringes. Enzo will request rehearing of that decision, both by the original panel and by the full en banc Court. Enzo believes rehearing is warranted by the panel’s failure to give appropriate weight to fact findings, including facts found by the jury, consistent with a broader construction of the patent, as required by the Supreme Court’s recent decision in Teva Pharmaceuticals (TEVA).
10:28 EDTTEVAOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE
08:44 EDTTEVAFDA warning on liquid bendamustine may help Eagle's EP-3102, says Piper Jaffray
Subscribe for More Information
March 13, 2015
10:51 EDTTEVAOptions with increasing implied volatility
Options with increasing implied volatility: PVA BBEP SLXP ENDP MYL BBBY TEVA ZTS
10:09 EDTGALEHigh option volume stocks
High option volume stocks: ULTA HOG CTIC CTL LOCO IMPV BMRN IMOS ATHX GALE
09:25 EDTGALEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FXCM (FXCM), up 15.8%... El Pollo LoCo (LOCO), up 9.9%... Ulta Salon (ULTA), up 7.1%... Hibbett Sports (HIBB), up 5.1%... Ann Inc (ANN), up 5.5%... Spectrum Pharmaceuticals (SPPI), up 2.9%. ALSO HIGHER: Herbalife (HLF), up 5.1% following a Wall Street Journal report that federal prosecutors are investigating potential stock manipulation... Mobileye (MBLY), up 4.7% after being upgraded at Goldman... NXP Semiconductors (NXPI), up 1.7% after being initiated with a Strong Buy at Needham. DOWN AFTER EARNINGS: Aeropostale (ARO), down 13.2%... CTI BioPharma (CTIC), down 7.7%... Civeo (CVEO), down 3.4%. ALSO LOWER: Galena Biopharma (GALE), down 10.4% after announcing public offering of common stock and warrants... Whiting Petroleum (WLL), down 7.6% following a report from Reuters that explains that the company looks to sell certain assets instead of the whole company... Continental Building (CBPX), down 7.5% after 5M share Spot Secondary priced at $19.70.
09:24 EDTGALEGalena Biopharma 24.359M share Spot Secondary priced at $1.56
Subscribe for More Information
05:47 EDTTEVAStocks with implied volatility movement; SLXP MNKD
Stocks with implied volatility movement; Salix (SLXP) 20, Teva (TEVA) 27 according to iVolatility.
March 12, 2015
19:25 EDTGALEOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTGALEGalena announces public offering of common stock and warrants
Subscribe for More Information
16:01 EDTTEVAOptions Update; March 12, 2015
Subscribe for More Information
12:49 EDTTEVAWHO recommends tenofovir or entecavir for hepatitis B treatment
The World Health Organization issued its first-ever guidance for the treatment of chronic hepatitis B. Its recommended medicines consist of Gilead's (GILD) tenofovir or Bristol-Myers' (BMY) entecavir. Teva (TEVA) has FDA approval for generic entecavir.
11:38 EDTTEVATeva volatility increases on share price rally
Subscribe for More Information
11:14 EDTTEVAPiper Jaffray biopharm analyst analyst/industry conference call at 12 pm
***TIME CHANGED TO 12pm from 11am on March 12***Biopharmaceuticals Analyst Schimmer, along with Dr. Bianca Weinstock-Guttman, discuss the current and future treatment paradigm and practice dynamics in MS on an Analyst/Industry conference call to be held on March 12.
08:09 EDTTEVATeva Mylan combination problematic for now, says Bernstein
Subscribe for More Information
05:55 EDTTEVAStocks with implied volatility movement; TEVA VRX
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use